Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial-Reference-Cited by-同舟云学术

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

Published:2020-09 Issue:3 Volume:78 Page:347-357
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Armstrong Andrew J.^ORCID,Lin Ping,Tombal Bertrand,Saad Fred,Higano Celestia S.,Joshua Anthony M.,Parli Teresa,Rosbrook Brad,van Os Steve,Beer Tomasz M.

Funder

Pfizer

Publisher

Elsevier BV

Subject

Urology

Reference28 articles.

1. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis;Armstrong;Clin Cancer Res,2007

2. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival;Armstrong;Eur J Cancer,2010

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer;Armstrong;Ann Oncol,2018

5. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer;Halabi;J Clin Oncol,2016

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatic Prostate Cancer: Sequential or Combination Therapy?;Clinical Genitourinary Cancer;2024-12

2. Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics;Radiotherapy and Oncology;2024-10

3. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-05

4. Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors;JCO Oncology Practice;2024-09

5. Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial;European Urology;2024-09